AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25464907 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC 15.6 mcg once daily (OD)
Number of subjects: 350
Study 25464907 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC 125 mcg once daily (OD)
Number of subjects: 350
Study 25464907 — intervention group
Group type: COMPARATOR
Intervention: UMEC (various doses)
Number of subjects: 350
Study 25464907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 23305962 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy
Number of subjects: 78
Study 23305962 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (in concurrent study)
Number of subjects: 78
Study 21353673 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg letrozole daily for 7 days
Number of subjects: 17
Study 21353673 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical controls)
Number of subjects: 17
Study 19152549 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 500 mg
Number of subjects: 15
Study 19152549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 15
Study 19152549 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone 1 g
Number of subjects: 15
Study 19152549 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg
Number of subjects: 15
Study 17415139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse therapy (300 mg dexamethasone for 3 consecutive days followed by 4 days of placebo)
Number of subjects: 81
Study 17415139 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (prednisone 70 mg per day tapered in steps of 10 mg per day to 0 mg)
Number of subjects: 81
Study 16506546 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC (12mg/kg body weight)
Number of subjects: 60
Study 16506546 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC + Ivermectin 200mcg (6mg/kg body weight + 200 mcg/kg body weight)
Number of subjects: 60
Study 16506546 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC + Ivermectin 400mcg (6mg/kg body weight + 400 mcg/kg body weight)
Number of subjects: 60
Study 16506546 — intervention group
Group type: COMPARATOR
Intervention: DEC alone
Number of subjects: 60
Study 17671254 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (200 mg each night) from 24 to 34 weeks of gestation
Number of subjects: 250
Study 17671254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 17671254 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (200 mg each night)
Number of subjects: 250
Study 11090405 — intervention group
Group type: EXPERIMENTAL
Intervention: Unenhanced CT
Number of subjects: 93
Study 8723580 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (300 or 600 IU/kg) administered three times (days 1, 4, and 7)
Number of subjects: 112
Study 8723580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 1910162 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed computer-generated appointment reminders
Number of subjects: 901
Study 1910162 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 901
Study 6125676 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 500 mg and clavulanic acid 125 mg
Number of subjects: 100
Study 6125676 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 500 mg and clavulanic acid 250 mg
Number of subjects: 100
Study 6125676 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 500 mg
Number of subjects: 100
Study 31975053 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF) - eating <8 hours per day for 6 weeks
Number of subjects: 0
Study 31975053 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF)
Number of subjects: 0
Study 31975053 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31740545 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC-NTF cells (n = 36)
Number of subjects: 48
Study 31740545 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 48
Study 29573081 — intervention group
Group type: EXPERIMENTAL
Intervention: AGV surgery with subconjunctival Bevacizumab (group 2)
Number of subjects: 50
Study 29573081 — intervention group
Group type: COMPARATOR
Intervention: Conventional AGV surgery (group 1)
Number of subjects: 50
Study 26736036 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 162
Study 26736036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 25247908 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% + 1 μg/kg dexmedetomidine (Group BD)
Number of subjects: 60
Study 25247908 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% (Group B)
Number of subjects: 60
Study 25247908 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 25247908 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 60
Study 25247908 — intervention group
Group type: EXPERIMENTAL
Intervention: Group BD
Number of subjects: 60
Study 22475319 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine ER
Number of subjects: 258
Study 22475319 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 258
Study 20605648 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO) - 100% oxygen at 2.4 atmospheres absolute for 100 min on 30 occasions over 6 weeks.
Number of subjects: 58
Study 20605648 — intervention group
Group type: COMPARATOR
Intervention: Best standard care (control group)
Number of subjects: 58
Study 18036976 — intervention group
Group type: EXPERIMENTAL
Intervention: Work to Tolerance (WTT) exercise group
Number of subjects: 35
Study 18036976 — intervention group
Group type: EXPERIMENTAL
Intervention: Work to Quota (WTQ) exercise group
Number of subjects: 35
Study 18036976 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 18036976 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of WTT and WTQ groups
Number of subjects: 35
Study 16075824 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment in Northern Americas (NA)
Number of subjects: 22576
Study 16075824 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment in Caribbean (CA)
Number of subjects: 22576
Study 16075824 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment in Eurasia (EA)
Number of subjects: 22576
Study 16075824 — intervention group
Group type: COMPARATOR
Intervention: All-cause mortality, fatal or nonfatal MI, fatal or nonfatal stroke, newly diagnosed diabetes in Northern Americas (NA)
Number of subjects: 22576
Study 12436031 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic barbiturate therapy
Number of subjects: 0
Study 12436031 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0
Study 12436031 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 0
Study 12436031 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective head cooling
Number of subjects: 0
Study 12436031 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic mild hypothermia
Number of subjects: 0
Study 12436031 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate and calcium channel blockers
Number of subjects: 0
Study 12436031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 9935200 — intervention group
Group type: EXPERIMENTAL
Intervention: INK4A deletion (4/55 cases)
Number of subjects: 79
Study 9935200 — intervention group
Group type: EXPERIMENTAL
Intervention: CDK4 gene amplification (6/67 samples)
Number of subjects: 79
Study 9935200 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alterations (INK4A and CDK4)
Number of subjects: 79
Study 9935200 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic lesions deregulating the G1 to S cell cycle checkpoint
Number of subjects: 79
Study 8520164 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + MPA
Number of subjects: 64
Study 8520164 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF
Number of subjects: 64
Study 8520164 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA alone
Number of subjects: 64
Study 8520164 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA
Number of subjects: 64
Study 8520164 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA and CAF + MPA
Number of subjects: 64
Study 2106545 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily infusions of 200 cc of a 20% lipid emulsion with TPN for the first week, followed by daily intravenous lipid for the next 3 weeks (0.7 g lipid/kg BW/day and approximately 280 mg of choline/day)
Number of subjects: 25
Study 2106545 — intervention group
Group type: COMPARATOR
Intervention: TPN without lipid for the first week, followed by daily intravenous lipid for the next 3 weeks
Number of subjects: 25
Study 31471494 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous needle drainage
Number of subjects: 31
Study 31753198 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial shunt device (IASD)
Number of subjects: 79
Study 29788133 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Music and Imagery (GrpMI) intervention
Number of subjects: 56
Study 29788133 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional service)
Number of subjects: 56
Study 27143873 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysozyme (270 mg) administered orally for 52 weeks as an add-on to standard therapies
Number of subjects: 408
Study 27143873 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally for 52 weeks as an add-on to standard therapies
Number of subjects: 408
Study 24529135 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 830
Study 22194217 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 103
Study 22194217 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ‐1a
Number of subjects: 103
Study 19963442 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-resistant subjects with impaired fasting glycaemia (IFG)
Number of subjects: 90
Study 19963442 — intervention group
Group type: COMPARATOR
Intervention: Insulin-resistant subjects with normal glucose regulation (NGR)
Number of subjects: 90
Study 19963442 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) subjects
Number of subjects: 90
Study 17957417 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Simultaneous Medical Interpreting (RSMI)
Number of subjects: 1276
Study 17957417 — intervention group
Group type: COMPARATOR
Intervention: Usual and Customary (U&C)
Number of subjects: 1276
Study 15721501 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg ingestion (2 eggs daily for 6 weeks)
Number of subjects: 49
Study 15721501 — intervention group
Group type: COMPARATOR
Intervention: Oat ingestion (oats daily for 6 weeks)
Number of subjects: 49
Study 11993588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular screening
Number of subjects: 1000
Study 11993588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer screening
Number of subjects: 1000
Study 11993588 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management
Number of subjects: 1000
Study 11993588 — intervention group
Group type: EXPERIMENTAL
Intervention: General lifestyle advice
Number of subjects: 1000
Study 9445307 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (inhaled corticosteroid)
Number of subjects: 0
Study 9445307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7611203 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (524 mg q.i.d.) and metronidazole (250 mg q.i.d. for the first 2 weeks) for 4 weeks
Number of subjects: 100
Study 7611203 — intervention group
Group type: COMPARATOR
Intervention: Control group (uninfected patients)
Number of subjects: 100
Study 7611203 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up (mean, 34 months)
Number of subjects: 100
Study 2121552 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA)
Number of subjects: 48
Study 2121552 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropins alone
Number of subjects: 48
Study 628361 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g probenecid
Number of subjects: 39
Study 628361 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day benzbromaron
Number of subjects: 39
Study 628361 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day benzbromaron
Number of subjects: 39
Study 628361 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/day probenecid
Number of subjects: 39
Study 30635187 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifecta biological valve
Number of subjects: 90
Study 30635187 — intervention group
Group type: COMPARATOR
Intervention: Mosaic Ultra biological valve
Number of subjects: 90
Study 27914318 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressor
Number of subjects: 60
Study 27914318 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 60
Study 25844569 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for type 2 diabetes risk
Number of subjects: 409
Study 25844569 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise
Number of subjects: 409
Study 25844569 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle changes
Number of subjects: 409
Study 25844569 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in genetic causality
Number of subjects: 409
Study 22314758 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific information about games using the interactive software 'Amazing Chateau'
Number of subjects: 81
Study 22314758 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational emotive education (REE)
Number of subjects: 81
Study 22314758 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 21552190 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer monitor viewed through goggles providing 40 lux of short-wavelength (blue) light
Number of subjects: 21
Study 21552190 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer monitor only
Number of subjects: 21
Study 21552190 — intervention group
Group type: COMPARATOR
Intervention: Dark control (orange-tinted safety glasses)
Number of subjects: 21
Study 18445058 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (N/S) infusion at a rate of 800 ml/hour during DSE
Number of subjects: 100
Study 18445058 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine alone
Number of subjects: 100
Study 15943850 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 20 mg bd
Number of subjects: 13
Study 15943850 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 15 mg daily
Number of subjects: 13
Study 12434937 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, moderate intensity exercise program
Number of subjects: 96
Study 12434937 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 96
Study 10217000 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative plasma levels of prothrombin fragment 1 + 2 (F1 + 2)
Number of subjects: 159
Study 10217000 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative plasma levels of thrombin-antithrombin III complexes (TAT)
Number of subjects: 159
Study 10217000 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative plasma levels of D-dimer
Number of subjects: 159
Study 7564481 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of oral methotrexate weekly
Number of subjects: 24
Study 7564481 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 24
Study 1941668 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal Indicator Wax
Number of subjects: 0
Study 1941668 — intervention group
Group type: EXPERIMENTAL
Intervention: Accufilm
Number of subjects: 0
Study 1941668 — intervention group
Group type: COMPARATOR
Intervention: T-Scan system
Number of subjects: 0
Study 7006657 — intervention group
Group type: EXPERIMENTAL
Intervention: dezocine 10 mg
Number of subjects: 160
Study 7006657 — intervention group
Group type: EXPERIMENTAL
Intervention: dezocine 15 mg
Number of subjects: 160
Study 7006657 — intervention group
Group type: COMPARATOR
Intervention: morphine 10 mg
Number of subjects: 160
Study 7006657 — intervention group
Group type: EXPERIMENTAL
Intervention: dezocine 5 mg
Number of subjects: 160
Study 7006657 — intervention group
Group type: EXPERIMENTAL
Intervention: dezocine (all doses)
Number of subjects: 160
Study 30146654 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-lecture
Number of subjects: 20
Study 30146654 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based learning (LBL)
Number of subjects: 20
Study 28770268 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong anchoring with large activity in contractile droplets (planar anchoring)
Number of subjects: 0
Study 28770268 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong anchoring with large activity in extensile droplets (normal anchoring)
Number of subjects: 0
Study 28770268 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuning activity and anchoring strength
Number of subjects: 0
Study 28770268 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous rotations under strong anchoring
Number of subjects: 0
Study 25622538 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) 1.2 g
Number of subjects: 48
Study 25622538 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) 2.4 g
Number of subjects: 48
Study 25622538 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) 4.8 g
Number of subjects: 48
Study 25622538 — intervention group
Group type: COMPARATOR
Intervention: Guanidinoacetic acid (GAA)
Number of subjects: 48
Study 24171842 — intervention group
Group type: EXPERIMENTAL
Intervention: Football Fans in Training (FFIT) programme for 12 weeks
Number of subjects: 103
Study 24171842 — intervention group
Group type: COMPARATOR
Intervention: Waitlist comparison group (received FFIT after four months)
Number of subjects: 103
Study 24171842 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity and diet improvements
Number of subjects: 103
Study 21183154 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis based on Nugent score ≥7
Number of subjects: 949
Study 21183154 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis based on vaginal fluid pH ≥5
Number of subjects: 949
Study 21183154 — intervention group
Group type: EXPERIMENTAL
Intervention: Nugent score and vaginal fluid pH
Number of subjects: 949
Study 21183154 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for relevant covariates
Number of subjects: 949
Study 18838053 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 µg/day for one year
Number of subjects: 865
Study 16026869 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day, 300 mg loading dose within 24 h prior to hospital admission) plus standard therapy (including ASA, 75‐325 mg/day) for 1 year
Number of subjects: 1000
Study 16026869 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone (including ASA, 75‐325 mg/day) for life
Number of subjects: 1000
Study 15556258 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600 IU=540 mg vitamin E emulsion)
Number of subjects: 68
Study 15556258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 11230896 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing with water and soap
Number of subjects: 99
Study 11230896 — intervention group
Group type: COMPARATOR
Intervention: No washing
Number of subjects: 99
Study 9260005 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA patch
Number of subjects: 51
Study 9260005 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 51
Study 8234958 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction training
Number of subjects: 28
Study 8234958 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 28
Study 2894219 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipipanone 8 mg
Number of subjects: 0
Study 2894219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 and 20 mg
Number of subjects: 0
Study 2894219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30068393 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based platform
Number of subjects: 0
Study 30068393 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based platform plus online dietician assistance
Number of subjects: 0
Study 30068393 — intervention group
Group type: COMPARATOR
Intervention: Waitlist with minimal intervention
Number of subjects: 0
Study 27765010 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 65
Study 27765010 — intervention group
Group type: COMPARATOR
Intervention: Control (Granisetron)
Number of subjects: 65
Study 27765010 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 65
Study 25100106 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous progesterone (Prolutex) 25 mg daily
Number of subjects: 800
Study 25100106 — intervention group
Group type: COMPARATOR
Intervention: Vaginal progesterone (Endometrin) 100 mg bid daily
Number of subjects: 800
Study 25100106 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous progesterone (Prolutex)
Number of subjects: 800
Study 25100106 — intervention group
Group type: COMPARATOR
Intervention: Vaginal progesterone (Endometrin)
Number of subjects: 800
Study 22497752 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 100 μg
Number of subjects: 79
Study 22497752 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg
Number of subjects: 79
Study 22497752 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg
Number of subjects: 79
Study 22497752 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 μg
Number of subjects: 79
Study 22497752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 20430356 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer trainer
Number of subjects: 43